Literature DB >> 28247189

Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child.

Haruko Iwabuchi1, Hiroyuki Kawashima2, Hajime Umezu3, Takayuki Takachi1, Masaru Imamura1, Akihiko Saitoh1, Akira Ogose2, Chihaya Imai4.   

Abstract

Histiocytic sarcoma, a rare hematopoietic neoplasm with evidence of histiocytic differentiation, is often refractory to conventional chemotherapy and radiotherapy, and its prognosis is generally dismal. The optimal management of this malignancy has not been established. We report a case of 8-year-old girl with histiocytic sarcoma involving the left femur. The tumor rapidly responded to a combination of cladribine and high-dose cytosine arabinoside, an aggressive salvage regimen for refractory Langerhans cell histiocytosis, and became impalpable during the first cycle. The patient has remained in complete remission more than 7 years from diagnosis.

Entities:  

Keywords:  Cladribine; Cytosine arabinoside; Histiocytic sarcoma

Mesh:

Substances:

Year:  2017        PMID: 28247189     DOI: 10.1007/s12185-017-2202-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

Review 1.  Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification.

Authors:  Emiko Takahashi; Shigeo Nakamura
Journal:  J Clin Exp Hematop       Date:  2013

2.  Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy.

Authors:  Jessica L Heath; Shelly E Burgett; Ana M Gaca; Ronald Jaffe; Daniel S Wechsler
Journal:  Pediatr Blood Cancer       Date:  2014-05-29       Impact factor: 3.167

3.  Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage.

Authors:  TuDung T Nguyen; Erich J Schwartz; Robert B West; Roger A Warnke; Daniel A Arber; Yasodha Natkunam
Journal:  Am J Surg Pathol       Date:  2005-05       Impact factor: 6.394

4.  2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis.

Authors:  A Saven; K A Foon; L D Piro
Journal:  Ann Intern Med       Date:  1994-09-15       Impact factor: 25.391

5.  Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

Authors:  Jean Donadieu; Frederic Bernard; Max van Noesel; Mohamed Barkaoui; Odile Bardet; Rosella Mura; Maurizio Arico; Christophe Piguet; Virginie Gandemer; Corinne Armari Alla; Niels Clausen; Eric Jeziorski; Anne Lambilliote; Sheila Weitzman; Jan Inge Henter; Cor Van Den Bos
Journal:  Blood       Date:  2015-07-20       Impact factor: 22.113

6.  Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163.

Authors:  Jeffrey A Vos; Susan L Abbondanzo; Carol L Barekman; Joann W Andriko; Markku Miettinen; Nadine S Aguilera
Journal:  Mod Pathol       Date:  2005-05       Impact factor: 7.842

7.  Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Authors:  S A Pileri; T M Grogan; N L Harris; P Banks; E Campo; J K C Chan; R D Favera; G Delsol; C De Wolf-Peeters; B Falini; R D Gascoyne; P Gaulard; K C Gatter; P G Isaacson; E S Jaffe; P Kluin; D M Knowles; D Y Mason; S Mori; H-K Müller-Hermelink; M A Piris; E Ralfkiaer; H Stein; I-J Su; R A Warnke; L M Weiss
Journal:  Histopathology       Date:  2002-07       Impact factor: 5.087

8.  Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.

Authors:  D A Carson; D B Wasson; R Taetle; A Yu
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

9.  Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.

Authors:  Muneer H Abidi; Isaacson Tove; Rami B Ibrahim; Dan Maria; Edward Peres
Journal:  Am J Hematol       Date:  2007-10       Impact factor: 10.047

10.  Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine.

Authors:  Sung W Choi; Babu S Bangaru; C Daniel Wu; Jonathan L Finlay
Journal:  J Pediatr Hematol Oncol       Date:  2003-06       Impact factor: 1.289

View more
  3 in total

1.  Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report.

Authors:  Osamu Imataki; Makiko Uemura; Haruyuki Fujita; Norimitsu Kadowaki
Journal:  Mol Clin Oncol       Date:  2022-07-15

2.  A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.

Authors:  Yu Furui; Takashi Kurata; Kazutoshi Komori; Eriko Uchida; Yosuke Miyairi; Akihiro Chiba; Yoshifumi Ogiso; Kazuo Sakashita
Journal:  Int Cancer Conf J       Date:  2022-06-30

3.  Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.

Authors:  Shree Bose; Joanna Robles; Chad M McCall; Anand S Lagoo; Daniel S Wechsler; Gary R Schooler; David Van Mater
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.